For example, the upregulation of vimentin, one of the EMT markers, was found associated with poor clinical outcome in AML patients [14], and downregulation of ZEB1 in AML cells can inhibit the invasive ability [15]. This evidence concerns the gene VIM and acute myeloid leukemia.